Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
5.14
-0.06 (-1.15%)
At close: Aug 7, 2025, 4:00 PM
5.14
0.00 (0.00%)
Pre-market: Aug 8, 2025, 8:36 AM EDT
Ardelyx Revenue
Ardelyx had revenue of $97.66M in the quarter ending June 30, 2025, with 33.38% growth. This brings the company's revenue in the last twelve months to $386.15M, up 83.88% year-over-year. In the year 2024, Ardelyx had annual revenue of $333.62M with 168.06% growth.
Revenue (ttm)
$386.15M
Revenue Growth
+83.88%
P/S Ratio
3.17
Revenue / Employee
$977,585
Employees
395
Market Cap
1.24B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 333.62M | 209.16M | 168.06% |
Dec 31, 2023 | 124.46M | 72.30M | 138.61% |
Dec 31, 2022 | 52.16M | 42.06M | 416.57% |
Dec 31, 2021 | 10.10M | 2.53M | 33.36% |
Dec 31, 2020 | 7.57M | 2.29M | 43.36% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ARDX News
- 3 days ago - Ardelyx, Inc. (ARDX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Ardelyx Announces Changes to the Executive Leadership Team - GlobeNewsWire
- 3 days ago - Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 18 days ago - Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025 - GlobeNewsWire
- 2 months ago - Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer - GlobeNewsWire
- 2 months ago - Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025 - GlobeNewsWire
- 3 months ago - Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference - GlobeNewsWire
- 3 months ago - Ardelyx: Revenue Misses And Losses Widen Amid XPHOZAH Uncertainty - Seeking Alpha